The Nurr1 Ligand,1,1-bis(3′-Indolyl)-1-(p-Chlorophenyl)Methane, Modulates Glial Reactivity and Is Neuroprotective in MPTP-Induced Parkinsonism

The orphan nuclear receptor Nurr1 (also called nuclear receptor-4A2) regulates inflammatory gene expression in glial cells, as well as genes associated with homeostatic and trophic function in dopaminergic neurons. Despite these known functions of Nurr1, an endogenous ligand has not been discovered....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of pharmacology and experimental therapeutics 2018-06, Vol.365 (3), p.636-651
Hauptverfasser: Hammond, Sean L., Popichak, Katriana A., Li, Xi, Hunt, Lindsay G., Richman, Evan H., Damale, Pranav U., Chong, Edwin K.P., Backos, Donald S., Safe, Stephen, Tjalkens, Ronald B.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 651
container_issue 3
container_start_page 636
container_title The Journal of pharmacology and experimental therapeutics
container_volume 365
creator Hammond, Sean L.
Popichak, Katriana A.
Li, Xi
Hunt, Lindsay G.
Richman, Evan H.
Damale, Pranav U.
Chong, Edwin K.P.
Backos, Donald S.
Safe, Stephen
Tjalkens, Ronald B.
description The orphan nuclear receptor Nurr1 (also called nuclear receptor-4A2) regulates inflammatory gene expression in glial cells, as well as genes associated with homeostatic and trophic function in dopaminergic neurons. Despite these known functions of Nurr1, an endogenous ligand has not been discovered. We postulated that the activation of Nurr1 would suppress the activation of glia and thereby protect against loss of dopamine (DA) neurons after subacute lesioning with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Our previous studies have shown that a synthetic Nurr1 ligand, 1,1-bis(3′-indolyl)-1-(p-chlorophenyl)methane (C-DIM12), suppresses inflammatory gene expression in primary astrocytes and induces a dopaminergic phenotype in neurons. Pharmacokinetic analysis of C-DIM12 in mice by liquid chromatography-mass spectrometry demonstrated that approximately three times more compound concentrated in the brain than in plasma. Mice treated with four doses of MPTP + probenecid over 14 days were monitored for neurobehavioral function, loss of dopaminergic neurons, and glial activation. C-DIM12 protected against the loss of DA neurons in the substantia nigra pars compacta and DA terminals in the striatum, maintained a ramified phenotype in microglia, and suppressed activation of astrocytes. In vitro reporter assays demonstrated that C-DIM12 was an effective activator of Nurr1 transcription in neuronal cell lines. Computational modeling of C-DIM12 binding to the three-dimensional structure of human Nurr1 identified a high-affinity binding interaction with Nurr1 at the coactivator domain. Taken together, these data suggest that C-DIM12 is an activator of Nurr1 that suppresses glial activation and neuronal loss in vivo after treatment with MPTP, and that this receptor could be an efficacious target for disease modification in individuals with Parkinson’s disease and related disorders.
doi_str_mv 10.1124/jpet.117.246389
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5941193</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S002235652426804X</els_id><sourcerecordid>29626009</sourcerecordid><originalsourceid>FETCH-LOGICAL-c509t-a1ffbbfc40dcee8ab704a22214aee5f844068bce55f4ae7407e86d0cce96593f3</originalsourceid><addsrcrecordid>eNp1kc9uEzEQxi0EomnhzA35WKS4tb32_rkgVREtkZISoXC2vN7ZrsvGXtm7kXLjEXgWHoknwVGgggMnj2a-7zfyfAi9YfSKMS6uHwcYU1VccZFnZfUMzZjkjFBGs-doRinnJJO5PEPnMT5SykSSvURnvMp5Tmk1Q9-3HeD7KQSGV_ZBu2bO5ozUNl5mP7_9IEvX-P7QvyOMXA5k0fU--KEDl1prGDvtYI7Xvpl6PULEd73VPf4M2ox2b8cDTjy8jPgepmQLfoTjALB1eL3Zbo70yUCDNzp8tS56Z-PuFXrR6j7C69_vBfpy-2G7-EhWn-6Wi5sVMZJWI9Gsbeu6NYI2BqDUdUGF5pwzoQFkWwpB87I2IGWbOoWgBZR5Q42BKpdV1mYX6P2JO0z1DhLEjUH3agh2p8NBeW3VvxNnO_Xg90pWgrEqS4DrE8AEH2OA9snLqDqGo47hpKpQp3CS4-3fK5_0f9JIguokgPTxvYWgorHg0olsSKdTjbf_hf8CjUeijA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>The Nurr1 Ligand,1,1-bis(3′-Indolyl)-1-(p-Chlorophenyl)Methane, Modulates Glial Reactivity and Is Neuroprotective in MPTP-Induced Parkinsonism</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Hammond, Sean L. ; Popichak, Katriana A. ; Li, Xi ; Hunt, Lindsay G. ; Richman, Evan H. ; Damale, Pranav U. ; Chong, Edwin K.P. ; Backos, Donald S. ; Safe, Stephen ; Tjalkens, Ronald B.</creator><creatorcontrib>Hammond, Sean L. ; Popichak, Katriana A. ; Li, Xi ; Hunt, Lindsay G. ; Richman, Evan H. ; Damale, Pranav U. ; Chong, Edwin K.P. ; Backos, Donald S. ; Safe, Stephen ; Tjalkens, Ronald B.</creatorcontrib><description>The orphan nuclear receptor Nurr1 (also called nuclear receptor-4A2) regulates inflammatory gene expression in glial cells, as well as genes associated with homeostatic and trophic function in dopaminergic neurons. Despite these known functions of Nurr1, an endogenous ligand has not been discovered. We postulated that the activation of Nurr1 would suppress the activation of glia and thereby protect against loss of dopamine (DA) neurons after subacute lesioning with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Our previous studies have shown that a synthetic Nurr1 ligand, 1,1-bis(3′-indolyl)-1-(p-chlorophenyl)methane (C-DIM12), suppresses inflammatory gene expression in primary astrocytes and induces a dopaminergic phenotype in neurons. Pharmacokinetic analysis of C-DIM12 in mice by liquid chromatography-mass spectrometry demonstrated that approximately three times more compound concentrated in the brain than in plasma. Mice treated with four doses of MPTP + probenecid over 14 days were monitored for neurobehavioral function, loss of dopaminergic neurons, and glial activation. C-DIM12 protected against the loss of DA neurons in the substantia nigra pars compacta and DA terminals in the striatum, maintained a ramified phenotype in microglia, and suppressed activation of astrocytes. In vitro reporter assays demonstrated that C-DIM12 was an effective activator of Nurr1 transcription in neuronal cell lines. Computational modeling of C-DIM12 binding to the three-dimensional structure of human Nurr1 identified a high-affinity binding interaction with Nurr1 at the coactivator domain. Taken together, these data suggest that C-DIM12 is an activator of Nurr1 that suppresses glial activation and neuronal loss in vivo after treatment with MPTP, and that this receptor could be an efficacious target for disease modification in individuals with Parkinson’s disease and related disorders.</description><identifier>ISSN: 0022-3565</identifier><identifier>EISSN: 1521-0103</identifier><identifier>DOI: 10.1124/jpet.117.246389</identifier><identifier>PMID: 29626009</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine - pharmacology ; Active Transport, Cell Nucleus - drug effects ; Animals ; Brain - drug effects ; Brain - metabolism ; Brain - pathology ; Cell Count ; Cell Nucleus - drug effects ; Cell Nucleus - metabolism ; Dopaminergic Neurons - drug effects ; Dopaminergic Neurons - metabolism ; Dopaminergic Neurons - pathology ; Gene Expression Regulation - drug effects ; Indoles - metabolism ; Indoles - pharmacokinetics ; Indoles - pharmacology ; Indoles - therapeutic use ; Ligands ; Male ; Mice ; Mice, Inbred C57BL ; Neuroglia - drug effects ; Neuroglia - pathology ; Neuropharmacology ; Neuroprotective Agents - metabolism ; Neuroprotective Agents - pharmacokinetics ; Neuroprotective Agents - pharmacology ; Neuroprotective Agents - therapeutic use ; NF-kappa B - metabolism ; Nuclear Receptor Subfamily 4, Group A, Member 2 - metabolism ; Parkinsonian Disorders - chemically induced ; Parkinsonian Disorders - drug therapy ; Parkinsonian Disorders - metabolism ; Parkinsonian Disorders - pathology ; Phenotype ; Signal Transduction - drug effects ; Tissue Distribution</subject><ispartof>The Journal of pharmacology and experimental therapeutics, 2018-06, Vol.365 (3), p.636-651</ispartof><rights>2018 American Society for Pharmacology and Experimental Therapeutics</rights><rights>Copyright © 2018 by The Author(s).</rights><rights>Copyright © 2018 by The Author(s) 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c509t-a1ffbbfc40dcee8ab704a22214aee5f844068bce55f4ae7407e86d0cce96593f3</citedby><cites>FETCH-LOGICAL-c509t-a1ffbbfc40dcee8ab704a22214aee5f844068bce55f4ae7407e86d0cce96593f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,778,782,883,27907,27908</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29626009$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hammond, Sean L.</creatorcontrib><creatorcontrib>Popichak, Katriana A.</creatorcontrib><creatorcontrib>Li, Xi</creatorcontrib><creatorcontrib>Hunt, Lindsay G.</creatorcontrib><creatorcontrib>Richman, Evan H.</creatorcontrib><creatorcontrib>Damale, Pranav U.</creatorcontrib><creatorcontrib>Chong, Edwin K.P.</creatorcontrib><creatorcontrib>Backos, Donald S.</creatorcontrib><creatorcontrib>Safe, Stephen</creatorcontrib><creatorcontrib>Tjalkens, Ronald B.</creatorcontrib><title>The Nurr1 Ligand,1,1-bis(3′-Indolyl)-1-(p-Chlorophenyl)Methane, Modulates Glial Reactivity and Is Neuroprotective in MPTP-Induced Parkinsonism</title><title>The Journal of pharmacology and experimental therapeutics</title><addtitle>J Pharmacol Exp Ther</addtitle><description>The orphan nuclear receptor Nurr1 (also called nuclear receptor-4A2) regulates inflammatory gene expression in glial cells, as well as genes associated with homeostatic and trophic function in dopaminergic neurons. Despite these known functions of Nurr1, an endogenous ligand has not been discovered. We postulated that the activation of Nurr1 would suppress the activation of glia and thereby protect against loss of dopamine (DA) neurons after subacute lesioning with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Our previous studies have shown that a synthetic Nurr1 ligand, 1,1-bis(3′-indolyl)-1-(p-chlorophenyl)methane (C-DIM12), suppresses inflammatory gene expression in primary astrocytes and induces a dopaminergic phenotype in neurons. Pharmacokinetic analysis of C-DIM12 in mice by liquid chromatography-mass spectrometry demonstrated that approximately three times more compound concentrated in the brain than in plasma. Mice treated with four doses of MPTP + probenecid over 14 days were monitored for neurobehavioral function, loss of dopaminergic neurons, and glial activation. C-DIM12 protected against the loss of DA neurons in the substantia nigra pars compacta and DA terminals in the striatum, maintained a ramified phenotype in microglia, and suppressed activation of astrocytes. In vitro reporter assays demonstrated that C-DIM12 was an effective activator of Nurr1 transcription in neuronal cell lines. Computational modeling of C-DIM12 binding to the three-dimensional structure of human Nurr1 identified a high-affinity binding interaction with Nurr1 at the coactivator domain. Taken together, these data suggest that C-DIM12 is an activator of Nurr1 that suppresses glial activation and neuronal loss in vivo after treatment with MPTP, and that this receptor could be an efficacious target for disease modification in individuals with Parkinson’s disease and related disorders.</description><subject>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine - pharmacology</subject><subject>Active Transport, Cell Nucleus - drug effects</subject><subject>Animals</subject><subject>Brain - drug effects</subject><subject>Brain - metabolism</subject><subject>Brain - pathology</subject><subject>Cell Count</subject><subject>Cell Nucleus - drug effects</subject><subject>Cell Nucleus - metabolism</subject><subject>Dopaminergic Neurons - drug effects</subject><subject>Dopaminergic Neurons - metabolism</subject><subject>Dopaminergic Neurons - pathology</subject><subject>Gene Expression Regulation - drug effects</subject><subject>Indoles - metabolism</subject><subject>Indoles - pharmacokinetics</subject><subject>Indoles - pharmacology</subject><subject>Indoles - therapeutic use</subject><subject>Ligands</subject><subject>Male</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Neuroglia - drug effects</subject><subject>Neuroglia - pathology</subject><subject>Neuropharmacology</subject><subject>Neuroprotective Agents - metabolism</subject><subject>Neuroprotective Agents - pharmacokinetics</subject><subject>Neuroprotective Agents - pharmacology</subject><subject>Neuroprotective Agents - therapeutic use</subject><subject>NF-kappa B - metabolism</subject><subject>Nuclear Receptor Subfamily 4, Group A, Member 2 - metabolism</subject><subject>Parkinsonian Disorders - chemically induced</subject><subject>Parkinsonian Disorders - drug therapy</subject><subject>Parkinsonian Disorders - metabolism</subject><subject>Parkinsonian Disorders - pathology</subject><subject>Phenotype</subject><subject>Signal Transduction - drug effects</subject><subject>Tissue Distribution</subject><issn>0022-3565</issn><issn>1521-0103</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kc9uEzEQxi0EomnhzA35WKS4tb32_rkgVREtkZISoXC2vN7ZrsvGXtm7kXLjEXgWHoknwVGgggMnj2a-7zfyfAi9YfSKMS6uHwcYU1VccZFnZfUMzZjkjFBGs-doRinnJJO5PEPnMT5SykSSvURnvMp5Tmk1Q9-3HeD7KQSGV_ZBu2bO5ozUNl5mP7_9IEvX-P7QvyOMXA5k0fU--KEDl1prGDvtYI7Xvpl6PULEd73VPf4M2ox2b8cDTjy8jPgepmQLfoTjALB1eL3Zbo70yUCDNzp8tS56Z-PuFXrR6j7C69_vBfpy-2G7-EhWn-6Wi5sVMZJWI9Gsbeu6NYI2BqDUdUGF5pwzoQFkWwpB87I2IGWbOoWgBZR5Q42BKpdV1mYX6P2JO0z1DhLEjUH3agh2p8NBeW3VvxNnO_Xg90pWgrEqS4DrE8AEH2OA9snLqDqGo47hpKpQp3CS4-3fK5_0f9JIguokgPTxvYWgorHg0olsSKdTjbf_hf8CjUeijA</recordid><startdate>20180601</startdate><enddate>20180601</enddate><creator>Hammond, Sean L.</creator><creator>Popichak, Katriana A.</creator><creator>Li, Xi</creator><creator>Hunt, Lindsay G.</creator><creator>Richman, Evan H.</creator><creator>Damale, Pranav U.</creator><creator>Chong, Edwin K.P.</creator><creator>Backos, Donald S.</creator><creator>Safe, Stephen</creator><creator>Tjalkens, Ronald B.</creator><general>Elsevier Inc</general><general>The American Society for Pharmacology and Experimental Therapeutics</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20180601</creationdate><title>The Nurr1 Ligand,1,1-bis(3′-Indolyl)-1-(p-Chlorophenyl)Methane, Modulates Glial Reactivity and Is Neuroprotective in MPTP-Induced Parkinsonism</title><author>Hammond, Sean L. ; Popichak, Katriana A. ; Li, Xi ; Hunt, Lindsay G. ; Richman, Evan H. ; Damale, Pranav U. ; Chong, Edwin K.P. ; Backos, Donald S. ; Safe, Stephen ; Tjalkens, Ronald B.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c509t-a1ffbbfc40dcee8ab704a22214aee5f844068bce55f4ae7407e86d0cce96593f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine - pharmacology</topic><topic>Active Transport, Cell Nucleus - drug effects</topic><topic>Animals</topic><topic>Brain - drug effects</topic><topic>Brain - metabolism</topic><topic>Brain - pathology</topic><topic>Cell Count</topic><topic>Cell Nucleus - drug effects</topic><topic>Cell Nucleus - metabolism</topic><topic>Dopaminergic Neurons - drug effects</topic><topic>Dopaminergic Neurons - metabolism</topic><topic>Dopaminergic Neurons - pathology</topic><topic>Gene Expression Regulation - drug effects</topic><topic>Indoles - metabolism</topic><topic>Indoles - pharmacokinetics</topic><topic>Indoles - pharmacology</topic><topic>Indoles - therapeutic use</topic><topic>Ligands</topic><topic>Male</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Neuroglia - drug effects</topic><topic>Neuroglia - pathology</topic><topic>Neuropharmacology</topic><topic>Neuroprotective Agents - metabolism</topic><topic>Neuroprotective Agents - pharmacokinetics</topic><topic>Neuroprotective Agents - pharmacology</topic><topic>Neuroprotective Agents - therapeutic use</topic><topic>NF-kappa B - metabolism</topic><topic>Nuclear Receptor Subfamily 4, Group A, Member 2 - metabolism</topic><topic>Parkinsonian Disorders - chemically induced</topic><topic>Parkinsonian Disorders - drug therapy</topic><topic>Parkinsonian Disorders - metabolism</topic><topic>Parkinsonian Disorders - pathology</topic><topic>Phenotype</topic><topic>Signal Transduction - drug effects</topic><topic>Tissue Distribution</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hammond, Sean L.</creatorcontrib><creatorcontrib>Popichak, Katriana A.</creatorcontrib><creatorcontrib>Li, Xi</creatorcontrib><creatorcontrib>Hunt, Lindsay G.</creatorcontrib><creatorcontrib>Richman, Evan H.</creatorcontrib><creatorcontrib>Damale, Pranav U.</creatorcontrib><creatorcontrib>Chong, Edwin K.P.</creatorcontrib><creatorcontrib>Backos, Donald S.</creatorcontrib><creatorcontrib>Safe, Stephen</creatorcontrib><creatorcontrib>Tjalkens, Ronald B.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Journal of pharmacology and experimental therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hammond, Sean L.</au><au>Popichak, Katriana A.</au><au>Li, Xi</au><au>Hunt, Lindsay G.</au><au>Richman, Evan H.</au><au>Damale, Pranav U.</au><au>Chong, Edwin K.P.</au><au>Backos, Donald S.</au><au>Safe, Stephen</au><au>Tjalkens, Ronald B.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Nurr1 Ligand,1,1-bis(3′-Indolyl)-1-(p-Chlorophenyl)Methane, Modulates Glial Reactivity and Is Neuroprotective in MPTP-Induced Parkinsonism</atitle><jtitle>The Journal of pharmacology and experimental therapeutics</jtitle><addtitle>J Pharmacol Exp Ther</addtitle><date>2018-06-01</date><risdate>2018</risdate><volume>365</volume><issue>3</issue><spage>636</spage><epage>651</epage><pages>636-651</pages><issn>0022-3565</issn><eissn>1521-0103</eissn><abstract>The orphan nuclear receptor Nurr1 (also called nuclear receptor-4A2) regulates inflammatory gene expression in glial cells, as well as genes associated with homeostatic and trophic function in dopaminergic neurons. Despite these known functions of Nurr1, an endogenous ligand has not been discovered. We postulated that the activation of Nurr1 would suppress the activation of glia and thereby protect against loss of dopamine (DA) neurons after subacute lesioning with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Our previous studies have shown that a synthetic Nurr1 ligand, 1,1-bis(3′-indolyl)-1-(p-chlorophenyl)methane (C-DIM12), suppresses inflammatory gene expression in primary astrocytes and induces a dopaminergic phenotype in neurons. Pharmacokinetic analysis of C-DIM12 in mice by liquid chromatography-mass spectrometry demonstrated that approximately three times more compound concentrated in the brain than in plasma. Mice treated with four doses of MPTP + probenecid over 14 days were monitored for neurobehavioral function, loss of dopaminergic neurons, and glial activation. C-DIM12 protected against the loss of DA neurons in the substantia nigra pars compacta and DA terminals in the striatum, maintained a ramified phenotype in microglia, and suppressed activation of astrocytes. In vitro reporter assays demonstrated that C-DIM12 was an effective activator of Nurr1 transcription in neuronal cell lines. Computational modeling of C-DIM12 binding to the three-dimensional structure of human Nurr1 identified a high-affinity binding interaction with Nurr1 at the coactivator domain. Taken together, these data suggest that C-DIM12 is an activator of Nurr1 that suppresses glial activation and neuronal loss in vivo after treatment with MPTP, and that this receptor could be an efficacious target for disease modification in individuals with Parkinson’s disease and related disorders.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>29626009</pmid><doi>10.1124/jpet.117.246389</doi><tpages>16</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0022-3565
ispartof The Journal of pharmacology and experimental therapeutics, 2018-06, Vol.365 (3), p.636-651
issn 0022-3565
1521-0103
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5941193
source MEDLINE; Alma/SFX Local Collection
subjects 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine - pharmacology
Active Transport, Cell Nucleus - drug effects
Animals
Brain - drug effects
Brain - metabolism
Brain - pathology
Cell Count
Cell Nucleus - drug effects
Cell Nucleus - metabolism
Dopaminergic Neurons - drug effects
Dopaminergic Neurons - metabolism
Dopaminergic Neurons - pathology
Gene Expression Regulation - drug effects
Indoles - metabolism
Indoles - pharmacokinetics
Indoles - pharmacology
Indoles - therapeutic use
Ligands
Male
Mice
Mice, Inbred C57BL
Neuroglia - drug effects
Neuroglia - pathology
Neuropharmacology
Neuroprotective Agents - metabolism
Neuroprotective Agents - pharmacokinetics
Neuroprotective Agents - pharmacology
Neuroprotective Agents - therapeutic use
NF-kappa B - metabolism
Nuclear Receptor Subfamily 4, Group A, Member 2 - metabolism
Parkinsonian Disorders - chemically induced
Parkinsonian Disorders - drug therapy
Parkinsonian Disorders - metabolism
Parkinsonian Disorders - pathology
Phenotype
Signal Transduction - drug effects
Tissue Distribution
title The Nurr1 Ligand,1,1-bis(3′-Indolyl)-1-(p-Chlorophenyl)Methane, Modulates Glial Reactivity and Is Neuroprotective in MPTP-Induced Parkinsonism
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T11%3A41%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Nurr1%20Ligand,1,1-bis(3%E2%80%B2-Indolyl)-1-(p-Chlorophenyl)Methane,%20Modulates%20Glial%20Reactivity%20and%20Is%20Neuroprotective%20in%20MPTP-Induced%20Parkinsonism&rft.jtitle=The%20Journal%20of%20pharmacology%20and%20experimental%20therapeutics&rft.au=Hammond,%20Sean%20L.&rft.date=2018-06-01&rft.volume=365&rft.issue=3&rft.spage=636&rft.epage=651&rft.pages=636-651&rft.issn=0022-3565&rft.eissn=1521-0103&rft_id=info:doi/10.1124/jpet.117.246389&rft_dat=%3Cpubmed_cross%3E29626009%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/29626009&rft_els_id=S002235652426804X&rfr_iscdi=true